Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03316599 · ClinicalTrials.gov registry record · Phase 1
Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer
A Phase 1 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT03316599 is a Phase 1 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 26 participants.
The verdict
NCT03316599, a Phase 1 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.
Interventions
- DRUG Gemcitabine
- DRUG Nab-paclitaxel
- DRUG Ficlatuzumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2018-01-17 |
| Est. Completion | 2021-07-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03316599
The ClinicalTrials.gov registry entry for NCT03316599 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Gemcitabine is the first listed.
NCT03316599 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03316599 about?
NCT03316599 is a clinical study titled "Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab (AV-299) in Patients With Advanced Pancreatic Cancer". To identify the maximally tolerated dose of ficlatuzumab when combined with nab-paclitaxel and gemcitabine in patients with previously untreated pancreatic cancer.
What is the current status of trial NCT03316599?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2018-01-17. Estimated completion is 2021-07-29.
What interventions are being tested in trial NCT03316599?
The interventions under investigation include: Gemcitabine (DRUG), Nab-paclitaxel (DRUG), Ficlatuzumab (DRUG).
Who is sponsoring clinical trial NCT03316599?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.